Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 4/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425231 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL11214006 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL1432909 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL11212280 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL56187 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL24049286 | 0.90 | BIRC2 (0.54) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| Bromide SCHEMBL5062038 | 0.89 | BIRC2 (0.52) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11592748 | 0.89 | BIRC2 (0.52) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17801789 | 0.89 | BIRC2 (0.52) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17801790 | 0.89 | BIRC2 (0.52) | BIRC2FOLH1TAS1R3TAS1R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | BIRC2 1554/4885FOLH1 12/4885TAS1R3 4852/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | BIRC2 1554/4885FOLH1 12/4885TAS1R3 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.